• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (65)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Samuel A. Wells, Jr, MD; William G. Dilley, PhD; John A. Farndon, MD; George S. Leight, MD; Stephen B. Baylin, MD

Arch Intern Med. 1985;145(7):1248-1252.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Medullary thyroid carcinoma (MTC) was first described as a distinct clinical entity by Hazard et al¹ in 1959. Although the lesion was previously thought to be a variant of anaplastic thyroid carcinoma, these investigators appreciated that certain histologic characteristics distinguished it from other thyroid neoplasms. Actually, MTC is derived not from follicular or stromal elements but from neural crest cells, which in mammals are incorporated within the thyroid gland. In birds and fish these cells exist as a separate structure called the ultimobranchial body. In retrospect, it is surprising that MTC was not recognized sooner as being different from other thyroid malignant neoplasms because it has certain unique characteristics, including frequent involvement of both thyroid lobes, occurrence in a familial pattern with assocated endocrinopathies (multiple endocrine neoplasia [MEN] types IIa and IIb), the presence in the tumor of a substance with the histochemical staining properties of amyloid, and the . . . [Full Text PDF of this Article]

Author Affiliations

Footnotes

Reprint requests to Department of Surgery, Washington University School of Medicine, 4960 Audubon Ave, St Louis, MO 63110 (Dr Wells).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?